Efficacy and biomarker analysis of adavosertib in differentiated thyroid cancer Journal Article


Authors: Lu, Y. L.; Wu, M. H.; Lee, Y. Y.; Chou, T. C.; Wong, R. J.; Lin, S. F.
Article Title: Efficacy and biomarker analysis of adavosertib in differentiated thyroid cancer
Abstract: Differentiated thyroid cancer (DTC) patients are usually known for their excellent prog-noses. However, some patients with DTC develop refractory disease and require novel therapies with different therapeutic mechanisms. Targeting Wee1 with adavosertib has emerged as a novel strategy for cancer therapy. We determined the effects of adavosertib in four DTC cell lines. Ada-vosertib induces cell growth inhibition in a dose-dependent fashion. Cell cycle analyses revealed that cells were accumulated in the G2/M phase and apoptosis was induced by adavosertib in the four DTC tumor cell lines. The sensitivity of adavosertib correlated with baseline Wee1 expression. In vivo studies showed that adavosertib significantly inhibited the xenograft growth of papillary and follicular thyroid cancer tumor models. Adavosertib therapy, combined with dabrafenib and trametinib, had strong synergism in vitro, and revealed robust tumor growth suppression in vivo in a xenograft model of papillary thyroid cancer harboring mutant BRAFV600E, without appreciable toxicity. Furthermore, combination of adavosertib with lenvatinib was more effective than either agent alone in a xenograft model of follicular thyroid cancer. These results show that adavosertib has the potential in treating DTC. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Keywords: sorafenib; combination therapy; differentiated thyroid cancer; dabrafenib; trametinib; lenvatinib; wee1; adavosertib
Journal Title: Cancers
Volume: 13
Issue: 14
ISSN: 2072-6694
Publisher: MDPI  
Date Published: 2021-07-01
Start Page: 3487
Language: English
DOI: 10.3390/cancers13143487
PROVIDER: scopus
PMCID: PMC8306685
PUBMED: 34298699
DOI/URL:
Notes: Article -- Export Date: 2 August 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Richard J Wong
    412 Wong
  2. Ting-Chao Chou
    319 Chou